TelyRx Holdings Inc. is making waves on the TSX with a significant one-day gain.
TelyRx Holdings Inc. (TELY.TO) is up today, showing a solid increase of 5.49% to close at CA$2.69. Investors seem to be responding positively to the company's recent financial results and growth trajectory.
Advertisement
TelyRx Holdings Inc.
TELY.TO
TELY.TO
TelyRx Holdings Inc.
WealthAwesomeMarket cap
$67.78M
52W high
$4.25
52W low
$2.00
1W change
-1.92%
Analyst Price Targets
Based on analyst covering TELY
Wall Street analysts forecast TELY stock price to rise 135.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+135.3% Upside
Current Price
C$2.55
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TELY's historical volatility
30-Day Vol
103.5%
Annualized
90-Day Vol
100.8%
Annualized
Trend (90d)
-37.8%
Annualized drift
90d Mean
C$2.23
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.44 | C$1.71 – C$3.48 |
| 60 trading days | C$2.33 | C$1.41 – C$3.86 |
| 90 trading days | C$2.23 | C$1.20 – C$4.14 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: With a market cap of CA$67.8 million and a notable increase in revenue, TelyRx is catching investor attention as it continues to expand its market presence.
5.49% Gain
TelyRx Holdings Inc. experienced a 5.49% increase in stock price today, reflecting positive market sentiment.
Bull case
The recent financial results show a strong upward trend in revenue, which grew significantly compared to previous quarters. The rise in prescriptions filled indicates that TelyRx is gaining traction in the market, which could lead to sustained growth.
Bear case
Despite the positive revenue growth, TelyRx is still operating at a loss, reporting a net loss of CA$4.7 million. Investors should stay cautious about the company's ability to turn a profit in the near future.
Strong Revenue Growth
Advertisement
TelyRx announced a revenue increase to CA$19.4 million in Q1 2026, up from CA$14.3 million in Q4 2025. This upward trend in revenue is a key factor driving investor interest and confidence in the stock.
Market Performance Metrics
With a market cap of CA$67.8 million, TelyRx is still in the early stages of its public trading journey. Investors should keep a close eye on the company's financial health, especially given its current net loss and negative profit margin.
Future Outlook
As TelyRx continues to expand its operations and fill more prescriptions, investors will be eager to see if the company can turn its revenue growth into profitability. The market's reaction today suggests optimism about its potential.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
